Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) Research & Development (2021 - 2025)

Historic Research & Development for Ernexa Therapeutics (ERNA) over the last 5 years, with Q3 2025 value amounting to $1.0 million.

  • Ernexa Therapeutics' Research & Development rose 339.66% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 349.56%. This contributed to the annual value of $4.6 million for FY2024, which is 2222.97% down from last year.
  • Per Ernexa Therapeutics' latest filing, its Research & Development stood at $1.0 million for Q3 2025, which was up 339.66% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Ernexa Therapeutics' Research & Development peaked at $5.0 million during Q3 2022, and registered a low of $987000.0 during Q2 2024.
  • For the 5-year period, Ernexa Therapeutics' Research & Development averaged around $1.6 million, with its median value being $1.5 million (2024).
  • Its Research & Development has fluctuated over the past 5 years, first soared by 23286.38% in 2022, then crashed by 7205.32% in 2023.
  • Quarter analysis of 5 years shows Ernexa Therapeutics' Research & Development stood at $1.5 million in 2021, then soared by 31.59% to $2.0 million in 2022, then crashed by 30.68% to $1.4 million in 2023, then dropped by 14.85% to $1.2 million in 2024, then decreased by 10.62% to $1.0 million in 2025.
  • Its Research & Development stands at $1.0 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.3 million for Q1 2025.